EP0799020A1 - Cosmetic and dermatological preparations with flavonoids - Google Patents
Cosmetic and dermatological preparations with flavonoidsInfo
- Publication number
- EP0799020A1 EP0799020A1 EP95941094A EP95941094A EP0799020A1 EP 0799020 A1 EP0799020 A1 EP 0799020A1 EP 95941094 A EP95941094 A EP 95941094A EP 95941094 A EP95941094 A EP 95941094A EP 0799020 A1 EP0799020 A1 EP 0799020A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- hair
- alpha
- skin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/19—Sheets or webs edge spliced or joined
- Y10T428/192—Sheets or webs coplanar
- Y10T428/193—Double faced corrugated sheets or webs connected
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/19—Sheets or webs edge spliced or joined
- Y10T428/192—Sheets or webs coplanar
- Y10T428/195—Beveled, stepped, or skived in thickness
Definitions
- the present invention relates in particular to cosmetic and dermatological preparations containing flavonoids, their glycosides and, if appropriate, their combinations with cinnamic acid derivatives or antioxidants.
- the damaging effect of the ultraviolet part of solar radiation on the skin is generally known. While rays with a wavelength shorter than 290 nm (the so-called (JVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns.
- JVC range the so-called (JVC range)
- the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
- UVB radiation which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole. It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
- UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
- Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals.
- Undefined radical photo products which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity.
- singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
- Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen normally present (radical ground state).
- UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
- antioxidants or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
- vitamin E a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
- the effect of solar radiation on the skin is, besides the formation of light swellings and tanning, mainly caused by the UVB area, a slow and progressive degradation of the connective tissue under the epidermis, caused by the longer-wave area of UVA sunlight, in which the elastic areas are exposed to radiation and strengthening fibers are destroyed.
- the weakening strength of the connective tissue leads to increased wrinkling and in extreme cases can lead to so-called "farmer's skin” or actinic keratosis. Wrinkles, wrinkles and dry skin that occur before the actual biological age due to environmental influences and the symptom of "premature skin aging" are considered as cosmetic undesirable " are.
- Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
- the object of the invention was therefore to provide cosmetic and dermatological active ingredients and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, but also normal skin exposed to the sun.
- the lips are an area of the face, which due to its structure and exposure is strongly exposed to and influenced by external influences.
- the naturally red color of the lips stems from the fact that lip skin, in contrast to "normal" skin, is much thinner, sweat and sebum glands are also missing. Melanin is significantly less present.
- the lack of some of the natural protection of the skin leads to lips being underneath Cold, heat and solar radiation are more exposed than normal skin, so protection and care of the lips are necessary in order to maintain a smooth, rosy appearance of the lips.If the lips were not adequately protected during exposure, the symptoms mentioned above can be seen Relief and elimination can also be seen as a cosmetic concern.
- the invention relates to preparations with extremely low so-called "stinging potential" and preparations against non-specific non-pathological itching.
- the skin especially the epidermis, as a barrier organ of the human organism, is particularly exposed to external influences.
- the skin represents an immunological organ, which as an immunocompetent peripheral compartment plays its own role in inductive, effective and regulative immune processes of the whole organism.
- the epidermis is rich with nerves and nerve end devices such as Vater-Pacini lamellar bodies, Merkel-cell-neurite complexes and free ones Nerve endings equipped for pain, cold, warmth and itching.
- nerve end devices such as Vater-Pacini lamellar bodies, Merkel-cell-neurite complexes and free ones Nerve endings equipped for pain, cold, warmth and itching.
- This "sensitive skin” differs fundamentally from “dry skin” with thickened and hardened horny layers.
- Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
- Typical disturbing neurosensory phenomena associated with the terms "stinging” or “sensitive skin” are reddening of the skin, tingling, tingling, tensing and burning of the skin and itching.
- the itching in atopic skin is to be regarded as a neurosensory phenomenon, as well as itching in skin diseases, which is only a symptom of these diseases and vice versa but also unspecific, i.e. without a clinical finding of a skin disorder, infection or irritation.
- unspecific itching is a first sign of a possible hidden general illness, it can also be triggered by stress or other environmental influences.
- “Stinging” phenomena can therefore generally be regarded as disorders to be treated cosmetically. Severe itching, on the other hand, particularly severe itching of the skin that occurs in atopy, can also be described as a more serious dermatological disorder, while itching that occurs during stinging or nonspecifically without a disease can also be regarded as a cosmetically treatable disorder.
- a "permeable" barrier is discussed, which is reflected in an increased TEWL.
- occlusive or lipid-substituting ones are used Products recommended that lower the TEWL after application.
- P.Elias even describes various lipid mixtures that cause barrier regeneration on mouse skin that has been damaged with acetone.
- the topical application of RRR-a-tocopherol has also been shown to improve the skin barrier.
- the dye chromophore is formed by the reaction of precursors (phenols, aminophenols, more rarely diamines) and bases (mostly p-phenylenediamine) with the oxidizing agent, mostly hydrogen peroxide. Hydrogen peroxide concentrations around 6% are usually used.
- the hydrogen peroxide also has a bleaching effect. Similar to bleached hair, microscopic holes in the areas where melanin granules were present can be detected in oxidatively colored human hair.
- the oxidizing agent hydrogen peroxide not only reacts with the color precursors, but also with the hair substance and can cause damage to the hair.
- Derivatives of thioglycolic acid are used in the permanent wave treatment of hair, which reduces the S-S bond of keratin and thus enables the hair to be deformed. Then the S-S bonds must be closed again by a so-called strengthener so that the deformation is retained.
- the permanent wave treatment takes place in an alkaline, neutral or acidic environment, in which the hair and scalp swell and react very sensitively.
- the scalp is also influenced during the dyeing process and during the perm.
- the skin keratin is attacked as well as the hair keratin.
- the skin of the hands can also be affected, because despite the recommended precautionary measures taken by the manufacturers of these products Gloves are worn or your hands come into contact with them when you rinse out the colors or permanent wave liquid.
- hair and scalp form a part of the body that is exposed to a considerable amount of UV radiation due to its position when staying outdoors. So far there are only a few products that take hair protection into account. Products that are applied to the hair and scalp after exposure to light, are known to alleviate the negative effects and thus keep the hair shiny and smooth, and to prevent or relieve scalp dandruff.
- Antioxidants are substances which prevent oxidation processes or which prevent the autoxidation of fats containing unsaturated compounds.
- Antioxidants which are also used in the fields of cosmetics and pharmacy are, for example, ⁇ -tocopherol, in particular in the form of ⁇ -tocopheryiacetate, sesamol, bile acid derivatives, butylated hydroxyanisole and butylated hydroxytoluene.
- Antioxidants or radical scavengers can also be incorporated into cosmetic formulations for the reason of preventing such reactions.
- antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidative action in light protection formulations, but the effect achieved here still falls far short of the hoped-for effect.
- An object of the present invention was to eliminate the disadvantages of the prior art.
- active ingredients or cosmetic and dermatological preparations containing such active ingredients should be made available, the use of which at least reduces, if not completely prevents, damage to the skin and / or hair by oxidative influence.
- Another object of the present invention was to provide cosmetic preparations which, before or after treatment of the hair with hair dye preparations or permanent wave products, even those containing strong oxidizing agents such as hydrogen peroxide, counteract their damaging oxidizing action.
- active ingredients and preparations containing such active ingredients should be made available for cosmetic and dermatological treatment and / or prophylaxis of the appearance of the "stinging".
- the invention relates to cosmetic and dermatological preparations
- a content of an active ingredient combination comprising a compound or more compounds selected from the group of flavonoids in combination with a compound or more compounds selected from the group of cinnamic acid derivatives and
- Active ingredient combinations b), their use and preparations containing them are preferred.
- Topical preparations are preferred.
- the flavonoids according to the invention are also referred to below with A), the cinnamic acid derivatives according to the invention also with B) and the antioxidants according to the invention also with C).
- Preferred flavonoids according to the invention are, for example, hydroxylated flavones, flavanones, isoflavones or chalcones and in each case also their glycosides, but also these non-hydroxylated basic structures or parent substances.
- the flavonoids A) are preferably selected from the group of substances of the generic structural formulas
- Zi - Z 5 are selected independently of one another from the group H, OH and O-alkyl, where the alkyl groups can be branched and unbranched and can have 1-18 C atoms, and wherein Gly is selected from the group of the mono-, di - And oligoglycoside residues or H can represent.
- Gly residues can be, for example, the residues specified for Gly1-Gly 3.
- Gly residues can be, for example, the residues specified for Glyi-Gly3.
- the flavonoid (s) A) from the group quercitin, chrysin, kaempferol, myricetin, apigenin, naringenin, hesperitin, morin, fisetin, vitexin, isovitexin, flavon and genistein.
- flavone glycosides A) from the group of rutin, rhamnetin, luteolin, naringin, hesperidin, phloridzin, diosmin, neohesperidin-dihydrochalcone.
- Chrysin, Naringin, Hesperidin, Naringenin, Hesperetin, Morin, Phloridzin, Diosmin, Neohesperidin-Dihydrochalkon, Flavon are particularly preferred.
- flavonoids A according to the invention are advantageously selected from the group of substances with the generic structural formulas:
- Zi - Z5 have the meaning given above and represent Glyi, Gly2 and Gly 3 monoglycoside residues.
- Gly 1t Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals or pentosyl radicals.
- Residues such as allosyl, altrosyl, apiosyl, arabinosyl, ascorbinyl, biosidyl, galactosyl, gulosyl, glucosyl, glucoronidyl, idosyl, mannosyl, talosyl, dulcityl, fructosyl, mannityl, rhamnosyl, ribosyl, sorbityl and xylosyl are advantageous to use. It is particularly advantageous to use rhamnosyl residues or glucosyl residues.
- flavone glycoside (s) from the group alpha-glucosylrutin, alpha-glucosylmyrictrin, alpha-glucosylisoquercitrin and alpha-glucosylquercitrin.
- alpha-glycosyl rutin alpha glycosyl hesperidine, alpha glycosyl naringin, alpha mannosyl rutin, alpha rhamnosyl rutin are particularly preferred.
- Glyi, Gly 2 , Gly 3 radicals from the group of the oligo- or poly-a- or ⁇ -glycosidic compounds, or from the group of the sugar acids or sugar esters.
- one or more Glyi, Gly 2 , Gly 3 residues can be selected from the group of substituted sugars, such as N-acetylglucosamine. It can also be of advantage to use flavonoids A) whose glycoside residue is bonded to 07, 04 ' , 03 ' or 05 ' via phenolic OH functions.
- flavonoids A flavonoids A
- chalcones the phenolic OH function of which is freely available at 09
- flavonoids A are: chrysin, naringin, hesperidin, naringenin, hesperetin, morin, phloridzin, diosmin, neohesperidin dihydrochalcone, flavone and in particular alpha-glucosylrutin of the formula:
- flavonoid-containing plant extracts for the purposes of the invention.
- These can be aqueous-alcoholic or aqueous-glycolic extracts and dry extracts obtained by the usual methods.
- the following have proven to be particularly advantageous: citrus fruit peel or kernel extract (e.g. Citricidal / Synthapharm), soy extract (e.g. Phytodermin / Chem. Laboratorium Dr. Kurt Richter GmbH), Sophora Japonica extract (e.g. B. Sophorine / Solabia), women's thistle extract (e.g.
- Suitable cinnamic acid derivatives are e.g. Hydroxycinnamic acids and their derivatives, the derivatives e.g. which can be defined below.
- cinnamic acid derivatives of the general formula can preferably be used
- the groups X, Y and R being able to be selected independently of one another from the group H, branched or unbranched alkyl having 1 to 18 carbon atoms, in particular 1 to 6 carbon atoms.
- the acids or their salts can be used, preferably the physiologically tolerable salts, for example water-soluble salts (sodium, potassium salts).
- Ferulic acid is regarded as a particularly advantageous cinnamic acid derivative for the purposes of the present invention.
- Ferulic acid (4-hydroxy-3-methoxycinnamic acid, caffeic acid-3-methyl ether) is due to the structural formula
- E-ferulic acid preference is given to using E-ferulic acid.
- Z-ferulic acid any mixtures of E- and Z-ferulic acid.
- caffeic acid Another derivative of cinnamic acid preferred according to the invention is caffeic acid, which is distinguished by its structure
- plant extracts containing cinnamic acid derivatives according to the invention in particular ferulic acid and / or caffeic acid.
- derivatives of caffeic acid or ferulic acid means their cosmetically or pharmacologically acceptable esters, salts and base adducts, in particular those as described above for the cinnamic acid derivatives.
- Preferred combinations according to the invention are combinations of one or more substances from the group of the flavonoids listed above or combinations of one or more representatives of the flavonoids with a derivative of cinnamic acid or the combination with several cinnamic acid derivatives.
- the weight ratio of the cinnamic acid derivatives to the flavonoid (s) is advantageously 25: 1 to 1:25, preferably 5: 1 to 1: 5, particularly preferably about 2: 1 to 1: 2.
- flavonoids flavonglucosides or flavonoid-containing plant extracts with ferulic acid
- synthetically modified, in particular glycosylated flavonoids such as alpha-glucosylrutin with cinnamic acid derivatives are particularly preferred according to the invention.
- Preparations with combinations b) which contain alpha-glucocsylrutin and / or ferulic acid are particularly preferred.
- the compounds of group A or of the combination of the active compounds A) and B) can be present as the sole active compounds in the preparations according to the invention.
- the cosmetic and dermatological preparations according to the invention preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight , based on the total weight of the preparation of one or more substances A) according to the invention or the combination of A) and B).
- the preparations according to the invention can preferably also have an antioxidant or more antioxidants C).
- the antioxidants C) according to the invention can be selected particularly advantageously from the group of tocopherols and their derivatives.
- the tocopherols also called vitamin E, are derived from the main body tocol ((2-methyl-2- (4,8,12-trimethyltridecyl) chroman-6-ol).
- the most common and most important tocopherol comes from the configuration 2R, 4'R, 8'R. It is sometimes called RRR- ⁇ -tocopherol.
- the tocopherol derivatives preferred according to the invention are the ⁇ -tocopherol and its esters, in particular the ⁇ -tocopheryl acetate. Esters of acids with 2 to 18, in particular 2 to 8, carbon atoms are preferred.
- antioxidants C) from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Camosin and its derivatives (e.g. Anserin), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (e.g.
- amino acids eg glycine, histidine, tyrosine, tryptophan
- imidazoles eg urocanic acid
- peptides such as D, L-carnosine, D-carnosine, L- Camosin and its derivatives (e.g. Anserin)
- carotenoids e.g. ⁇ -car
- thiols e.g. Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters
- salts and sulfoximine compounds eg buthionine suffoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathioninsulfoximine
- Dosages e.g. pmol to ⁇ mol / kg
- metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
- ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
- humic acid
- Bile acid Bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their
- Trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, sesamol, sesamolin, zinc and its derivatives e.g. ZnO, ZnSO.
- Selenium and its derivatives e.g. selenium methionine
- stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
- derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
- the amount of the aforementioned antioxidants C) (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight the preparation.
- vitamin E and / or its derivatives represent the antioxidant (s)
- the cosmetic and / or dermatological formulations according to the invention can be composed as usual and can be used for prophylaxis and / or for the treatment of the skin in the sense of a dermatological treatment or a prophylaxis and / or treatment in the sense of cosmetics. But they can also be used in make-up products in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the Total weight, one or more substances A) according to the invention or the combination of A) and B).
- the substances or preparations according to the invention containing such substances preferably combinations of flavonoids or their derivatives, cinnamic acid derivatives and, if appropriate, antioxidants are applied to the skin in a sufficient amount in the manner customary for cosmetics or dermatics.
- JP-OS Hei-06-138,941 describes oral preparations containing water-soluble glycosides, which can be selected, for example, from the group ⁇ -glucosylrutin, ⁇ -glucosylmyrictrin, ⁇ -glucosylisoquercitrin and ⁇ -glucosylquercitrin.
- JP-OS Hei-04- 363,395 describes a process for preventing the decomposition of perfume components, which is characterized, inter alia, by the addition of ⁇ -glucosylrutin to the corresponding preparations.
- the documents EP-OS 586 303 and EP-OS 595 694 describe the use of flavonoids as antioxidants or light protection substances in cosmetics.
- vitamin E and its derivatives according to the invention has not been suggested by the prior art.
- the active substances or combinations of active substances according to the invention for combating and / or prophylaxis of skin aging and inflammatory reactions caused by oxidative stress, and the effects and uses indicated above and below.
- the invention therefore also relates to the use of the cosmetic and dermatological preparations
- Topical application is preferred for this use.
- the cosmetic or dermatological formulations according to the invention can be composed as usual for these uses and e.g. for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the total weight of the agent, on the active substances according to the invention or their combinations of active substances.
- the cosmetic and dermatological preparations according to the invention are preferably applied in a sufficient amount to the skin and / or the hair for cosmetics.
- Cosmetic and dermatological preparations according to the invention can be in various forms.
- they can be a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, multiple emulsions, for example of the water- in-oil-in-water (W / O / W), a gel, a solid stick, an ointment or an aerosol.
- W / O water-in-oil-in-water
- W / O / W oil-in-water
- a gel for example of the water- in-oil-in-water (W / O / W)
- a gel for example of the water- in-oil-in-water (W / O / W)
- a solid stick for example of the water- in-oil-in-water (W / O / W)
- an aerosol ointment or an aerosol.
- active ingredient combinations according to the invention for protecting the skin and / or hair from oxidative stress is therefore also regarded as an advantageous embodiment of the present invention, in particular this use of the active ingredient combinations according to the invention in shampoos and wash formulations.
- the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- cosmetic auxiliaries e.g. Preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers
- preparations according to the invention can also contain antioxidants.
- antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
- the antioxidants are advantageously selected from the group consisting of
- Amino acids e.g. glycine, histidine, tyrosine, tryptophan
- derivatives e.g. glycine, histidine, tyrosine, tryptophan
- Imidazoles e.g. urocanic acid
- derivatives peptides such as D, L-camosine
- D-carnosine, L-carnosine and their derivatives e.g. anserine
- carotenoids e.g. carotenoids
- carotenes e.g. ⁇ -carotene, ß-carotene, lycopene
- chlorogenic acid and its derivatives e.g. dihydroliponic acid
- lipoic acid and its derivatives e.g. dihydroliponic acid
- Aurothioglucose, propylthiouracil and other thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl
- Lipids, nucleotides, nucleosides and salts) and sulfoximine compounds e.g.
- Buthioninsulfoximine Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-,
- Heptathioninsulfoximine in very low tolerable doses (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g. citric acid, lactic acid,
- ⁇ -linolenic acid e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
- folic acid and its derivatives e.g. ubiquinone and ubiquinol and their derivatives
- vitamin C and derivatives e.g.
- Ascorbyl palmitate Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and
- ZnO, ZnSO- selenium and its derivatives
- stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
- the derivatives salts , Esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
- the amount of the aforementioned antioxidants (one or more compounds), which are not identical to the active ingredient combinations according to the invention, in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1 - 10 wt .-%, based on the total weight of the preparation. If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
- vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
- Emulsions according to the invention are advantageous and contain e.g. the said fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
- oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
- Fats, waxes and other natural synthetic and / or partially synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
- Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof
- saturated compounds such as hydrocarbons of natural or synthetic origin (petroleum jelly, squalane)
- the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and whose ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose , particularly advantageously from the group of polyacrylates, preferably a polyacrylate from
- Water can also be a component of alcoholic solvents.
- Emulsions according to the invention are advantageous and contain e.g. the fats, oils, waxes and other fat bodies mentioned, as well as water and an emuigator, as is usually used for such a type of formulation.
- Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oleo-alcoholic gels and preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
- a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oleo-alcoholic gels and preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
- Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
- Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. , in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
- the emulsions according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble.
- Oil-soluble UVB filters which are advantageous according to the invention are, for example:
- 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
- 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentiester;
- esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
- benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
- Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, 2,4,6-trianilino- (p-carbo-2'-ethyl-1 '- hexyloxy) -1, 3,5-triazine.
- UVB filters examples include Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanoiammonium salt, and the sulfonic acid itself;
- Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
- Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and their salts.
- UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
- the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant in a cosmetic or dermatological preparation.
- UVA filters which have hitherto usually been contained in cosmetic preparations.
- These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4 '- isopropylphenyl) propane-1,3-dione.
- These combinations or preparations containing these combinations are also the subject of the invention.
- the amounts used for the UVB combination can be used.
- the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant in a cosmetic or dermatological preparation.
- the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter. Filters as an antioxidant in a cosmetic or dermatological preparation.
- Cosmetic and dermatological preparations with an effective content of active substances according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide.
- UVA filter and pigment or preparations containing this combination are also the subject of the invention.
- the amounts given for the above combinations can be used.
- Cosmetic and dermatological preparations for protecting the hair from UV rays according to the invention are, for example, shampooing agents, preparations which are used when rinsing the hair before or after the shampooing, before or after the permanent wave treatment, before or after the coloring or discoloration of the Hair is applied to preparations for blow-drying or pickling hair, preparations for coloring or decolouring, to a styling and treatment lotion, a hair lacquer or to permanent waving agents.
- the cosmetic and dermatological preparations contain active substances and auxiliaries as are usually used for this type of preparations for hair care and hair treatment.
- Preservatives, surface-active substances, substances to prevent foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments serve as auxiliary substances.
- electrolytes are understood to mean water-soluble alkali metal, ammonium, alkaline earth metal (including magnesium) and zinc salts of inorganic anions and any mixtures of such salts, it being necessary to ensure that these salts are pharmaceutical or distinguish cosmetic harmlessness.
- the anions according to the invention are preferably selected from the group of chlorides, sulfates and hydrogen sulfates, phosphates, hydrogen phosphates and linear and cyclic oligophosphates as well as carbonates and hydrogen carbonates.
- Cosmetic preparations which are a skin cleansing agent or shampoo contain preferably at least one anionic, non-ionic or amphoteric surface-active substance, or else mixtures of such substances, active substances according to the invention in an aqueous medium and auxiliaries as are usually used therefor.
- the surface-active substance or the mixtures of these substances can be present in the shampoo in a concentration of between 1% and 50% by weight.
- a lotion that is rinsed out and e.g. before or after decolorization, before or after shampooing, between two shampooing steps, before or after permanent waving, these are e.g. around aqueous or aqueous-alcoholic solutions, which may contain surface-active substances, the concentration of which may be between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight.
- a cosmetic preparation in the form of a lotion that is not rinsed out, in particular a lotion for inlaying the hair, a lotion used for blow-drying the hair, a styling and treatment lotion generally provides an aqueous, alcoholic or aqueous-alcoholic solution represents and contains at least one cationic, anionic, non-ionic or amphoteric polymer or mixtures thereof, as well as active ingredient combinations according to the invention in effective concentration.
- the amount of the polymers used is, for example, between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
- Cosmetic preparations for the treatment and care of the hair which contain active ingredients according to the invention, can be present as emulsions which are of the non-ionic or anionic type.
- non-ionic emulsions contain oils or fatty alcohols, which can also be polyethoxylated or polypropoxylated, for example, or also mixtures of the two organic components.
- These emulsions may contain cationic surface-active substances.
- cosmetic preparations for the treatment and care of the hair can be in the form of gels which, in addition to an effective content of active compound combinations according to the invention and solvents conventionally used for this, preferably water, or organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. Aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate, contain.
- the thickener is in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
- the amount of the active compounds according to the invention in an agent intended for the hair is preferably 0.05% by weight to 10% by weight, in particular 0.5% by weight to 5% by weight, based on the total weight of the agent.
- Aqueous cosmetic detergents according to the invention or low-water or water-free detergent concentrations intended for aqueous cleaning can contain anionic, nonionic and / or amphoteric surfactants, for example
- Cosmetic preparations which are cosmetic cleaning preparations for the skin, can be in liquid or solid form.
- they preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof, if desired one or more electrolytes and auxiliaries of the kind normally used for this purpose.
- the surface-active substance can be present in the cleaning preparations in a concentration of between 1 and 94% by weight, based on the total weight of the preparations.
- Cosmetic formulations which are shampoos s t hal ⁇ th preferably adjacent an effective content of novel active compounds thereof, an inventive electrolytes and auxiliaries as are customarily used for this purpose at least one anionic, nonionic or amphoteric surfactant or mixtures thereof, if necessary.
- the surface-active substance can be in a Concentration between 1 wt .-% and 94 wt .-% are present in the shampoo.
- compositions according to the invention contain water and, if appropriate, the additives customary in cosmetics, for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients and the like.
- the additives customary in cosmetics for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients and the like.
- the present invention also encompasses a cosmetic method for protecting the skin and hair from oxidative or photooxidative processes, which is characterized in that a cosmetic agent which contains an effective concentration of active compounds according to the invention is applied to the skin or hair in a sufficient amount applies.
- the present invention also includes a method for protecting cosmetic or dermatological preparations against oxidation or photo-oxidation, these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can cause stability problems due to oxidation or photooxidation during storage, characterized in that that the cosmetic preparations have an effective content of active ingredients according to the invention.
- these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can
- the amount of active compounds according to the invention in these preparations is preferably 0.001% by weight to 10% by weight, in particular 0.01% by weight to 6% by weight, based on the total weight of the preparations.
- the invention also relates to the process for the preparation of the preparations according to the invention, which is characterized in that Active ingredients according to the invention are incorporated into cosmetic and dermatological logical formulations in a manner known per se.
- Paraffin oil, pigments and dyes ad 100.00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE29522372U DE29522372U1 (en) | 1994-12-13 | 1995-12-12 | Cosmetic and dermatological preparations with flavonoids |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4444238A DE4444238A1 (en) | 1994-12-13 | 1994-12-13 | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
DE4444238 | 1994-12-13 | ||
PCT/EP1995/004905 WO1996018379A1 (en) | 1994-12-13 | 1995-12-12 | Cosmetic and dermatological preparations with flavonoids |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0799020A1 true EP0799020A1 (en) | 1997-10-08 |
Family
ID=6535603
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95118438A Withdrawn EP0716847A1 (en) | 1994-12-13 | 1995-11-23 | Cosmetic or dermatologic compositions containing cinnamic acid derivatives and a flavonoid |
EP95942128A Withdrawn EP0799022A1 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids for protecting unstable cosmetic active substances and constituents in cosmetic and dermatological formulations |
EP01123102A Withdrawn EP1201227A3 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions |
EP95942130A Revoked EP0799023B1 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
EP02025465A Withdrawn EP1300138A3 (en) | 1994-12-13 | 1995-12-12 | Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis |
EP95942129A Revoked EP0797427B1 (en) | 1994-12-13 | 1995-12-12 | Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides |
EP95941094A Ceased EP0799020A1 (en) | 1994-12-13 | 1995-12-12 | Cosmetic and dermatological preparations with flavonoids |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95118438A Withdrawn EP0716847A1 (en) | 1994-12-13 | 1995-11-23 | Cosmetic or dermatologic compositions containing cinnamic acid derivatives and a flavonoid |
EP95942128A Withdrawn EP0799022A1 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids for protecting unstable cosmetic active substances and constituents in cosmetic and dermatological formulations |
EP01123102A Withdrawn EP1201227A3 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions |
EP95942130A Revoked EP0799023B1 (en) | 1994-12-13 | 1995-12-12 | Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
EP02025465A Withdrawn EP1300138A3 (en) | 1994-12-13 | 1995-12-12 | Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis |
EP95942129A Revoked EP0797427B1 (en) | 1994-12-13 | 1995-12-12 | Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides |
Country Status (7)
Country | Link |
---|---|
US (8) | US5952373A (en) |
EP (7) | EP0716847A1 (en) |
JP (5) | JPH08259421A (en) |
AT (2) | ATE240092T1 (en) |
DE (5) | DE4444238A1 (en) |
ES (2) | ES2177673T3 (en) |
WO (4) | WO1996018382A1 (en) |
Families Citing this family (311)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE32570T1 (en) * | 1981-12-10 | 1988-03-15 | Revlon | PROCESS FOR MAKING METALLIC LEAF-FORMING PIGMENTS. |
DE4444238A1 (en) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
JPH1053515A (en) * | 1996-08-09 | 1998-02-24 | Ajinomoto Co Inc | Skin lotion |
US8039026B1 (en) * | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
DE19742025A1 (en) * | 1997-09-24 | 1999-03-25 | Beiersdorf Ag | Use of flavone or flavanone derivatives to treat or prevent undesirable skin pigmentation |
US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
AU1289899A (en) | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
DE69804657T2 (en) * | 1997-11-19 | 2002-11-28 | Flavone Sunproducts A/S, Naestved | A COMPOSITION CONTAINING OR MULTIPLE FLAVONIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A UV-ABSORBING AGENT |
JPH11180885A (en) * | 1997-12-18 | 1999-07-06 | Noevir Co Ltd | Antiallergic skin preparation for external use |
FR2772610B1 (en) * | 1997-12-19 | 2006-06-02 | Oreal | USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COSMETIC COMPOSITION |
FR2772613B1 (en) * | 1997-12-19 | 2003-05-09 | Oreal | USE OF PHLOROGLUCINOL IN A COSMETIC COMPOSITION |
FR2772612B1 (en) | 1997-12-19 | 2003-01-10 | Oreal | USE OF CINNAMIC ACID OR DERIVATIVES THEREOF IN A FIRMING COSMETIC COMPOSITION |
US6660283B2 (en) | 1997-12-19 | 2003-12-09 | Societe L'oreal S.A. | Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition |
DE19807774A1 (en) * | 1998-02-24 | 1999-08-26 | Beiersdorf Ag | Use of flavone, flavanone or flavonoid compound for protection of ascorbic acid or ascorbyl compound against oxidation, especially in cosmetic and dermatological preparations, |
BR9908870A (en) * | 1998-03-16 | 2000-11-21 | Procter & Gamble | Processes to regularize the appearance of the skin |
DE19811692A1 (en) * | 1998-03-18 | 1999-09-23 | Merck Patent Gmbh | Sunscreen formulation containing filters preventing herpes virus activation and herpetic skin disease |
FR2778560B1 (en) * | 1998-05-12 | 2001-06-01 | Oreal | USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN, AND COMPOSITION COMPRISING SAME |
US6750229B2 (en) | 1998-07-06 | 2004-06-15 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin pigmentation |
US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
FR2781156B1 (en) * | 1998-07-20 | 2001-06-29 | Lafon Labor | PHARMACEUTICAL COMPOSITION FOR PARTICULARLY FOR THE PREVENTION AND TREATMENT OF RADIOMUCITES AND CHEMOMUCITES |
DE19837758A1 (en) * | 1998-08-20 | 2000-02-24 | Beiersdorf Ag | Use of active ingredient combinations of flavonoids and UV filter substances as antiviral principle of action |
BR9906998A (en) * | 1998-09-10 | 2000-09-26 | Avon Prod Inc | Method and compositions to reduce dermatological aging and to reduce bruises |
DE19845305A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Active combination, useful in cosmetic and dermatological formulations, contains saturated fatty acid mono- and/or diglyceride esters partly neutralized with citric acid and flavone, flavanone and/or flavonoid |
DE19845319A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Use of mono-, oligo- and polymeric ethers, esters and ether-ester surfactants for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations |
DE19845322A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Active combination based on flavone, flavanone and/or flavonoid, useful in cosmetic and dermatological formulations, contains 2-tert.-butyl hydroquinone |
DE19845266A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Use of butylhydroxytoluene for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations |
DE19845324A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Use of nitrilotriacetic acid for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations |
DE19845271A1 (en) * | 1998-10-01 | 2000-04-06 | Beiersdorf Ag | Cosmetic or dermatological formulation containing flavone, flavanone and/or flavonoid, useful e.g. in skin and hair cosmetics, contains alkylglucoside and optionally alkanol |
US20020197244A1 (en) * | 1998-12-07 | 2002-12-26 | Miri Seiberg | Compositions and methods for regulating phagocytosis and ICAM-1 expression |
DE19903241A1 (en) * | 1999-01-28 | 2000-08-03 | Merck Patent Gmbh | Galenic wording |
DE19904703A1 (en) * | 1999-02-05 | 2000-08-24 | Georg Noga | Aqueous plant strengthening composition containing tocopherol and methoxycinnamic acid, providing protection against damage by e.g. heat, frost, drought or especially ultraviolet light |
JP2000239144A (en) * | 1999-02-22 | 2000-09-05 | Kose Corp | Langerhans cell decrease inhibitor and preparation which contain the inhibitor and is useful for external use for skin |
US6440432B1 (en) * | 1999-03-18 | 2002-08-27 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid |
AU3913800A (en) * | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
US20040235950A1 (en) * | 1999-05-20 | 2004-11-25 | Voorhees John J. | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
US7268148B2 (en) * | 1999-05-20 | 2007-09-11 | Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
DE19923713A1 (en) * | 1999-05-22 | 2000-11-23 | Beiersdorf Ag | Cosmetic or dermatological sunscreen preparations containing flavone derivatives and / or flavanone derivatives, in particular flavonoids and benzotriazole, and the use of UV filter substances having the structural motif of benzotriazole for stabilizing flavone derivatives and / or flavanone derivatives, in particular flavonoids |
DE19923712A1 (en) * | 1999-05-22 | 2000-11-23 | Beiersdorf Ag | Active substance combination of sulfonated UV filter substances and flavone derivatives and / or flavanone derivatives, in particular flavonoids, and cosmetic preparations containing such active substance combinations |
DE19923772A1 (en) * | 1999-05-22 | 2000-11-23 | Beiersdorf Ag | Active substance combinations of boron nitride and flavone derivatives and / or flavanone derivatives, in particular of flavonoids, and cosmetic preparations containing such active substance combinations |
DE19923715A1 (en) * | 1999-05-22 | 2000-11-23 | Beiersdorf Ag | Cosmetic or dermatological sunscreen preparations containing flavone derivatives and / or flavanone derivatives, in particular flavonoids and s-triazine, and the use of UV filter substances having the structural motif of s-triazine for stabilizing flavone derivatives and / or flavanone derivatives, in particular flavonoids |
DE19925499A1 (en) * | 1999-06-04 | 2000-12-07 | Beiersdorf Ag | Use of ascorbic acid and one or more flavone derivatives and / or flavonone derivatives, in particular flavonoids, for the preparation of cosmetic or dermatological preparations for the prophylaxis or relief of sunburn |
ES2252029T3 (en) * | 1999-07-20 | 2006-05-16 | Beiersdorf Ag | FINALLY DISPERSED SYSTEMS OF THE WATER TYPE IN OIL WITHOUT EMULSIONERS. |
DE19939849A1 (en) * | 1999-07-20 | 2001-01-25 | Beiersdorf Ag | Emulsifier-free, finely dispersed water-in-oil systems |
US6864274B2 (en) | 1999-07-23 | 2005-03-08 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6531500B2 (en) | 1999-07-23 | 2003-03-11 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
US20020054895A1 (en) | 1999-07-23 | 2002-05-09 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6896897B2 (en) | 1999-07-23 | 2005-05-24 | Alwyn Company, Inc. | Flexible applicator for applying oil-in-water emulsion with improved stability |
US6329413B1 (en) | 1999-07-23 | 2001-12-11 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6281236B1 (en) | 1999-07-23 | 2001-08-28 | Alwyn Company, Inc. | Oil-in-water emulsion with improved stability |
US6673826B2 (en) | 1999-07-23 | 2004-01-06 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
JP4540909B2 (en) * | 1999-07-26 | 2010-09-08 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Stabilization of ferulic acid in cosmetic compositions. |
US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
DE19938404A1 (en) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Cosmetic preparations |
JP3470182B2 (en) * | 1999-08-27 | 2003-11-25 | リアル化学株式会社 | Novel hair dye and hair dyeing method using the same |
US6667045B2 (en) * | 1999-10-01 | 2003-12-23 | Joseph Scott Dahle | Topical applications for skin treatment |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
AU7638300A (en) * | 1999-10-20 | 2001-04-30 | Vesifact Ag | Microemulsion preconcentrates and microemulsions |
US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
EP1104672A1 (en) * | 1999-12-02 | 2001-06-06 | Laboratoires Serobiologiques(Societe Anonyme) | Cosmetic and/or pharmaceutical compositions |
US6521668B2 (en) * | 1999-12-14 | 2003-02-18 | Avon Products, Inc. | Cosmetic composition and methods of use |
WO2001043702A1 (en) * | 1999-12-15 | 2001-06-21 | Kyowa Hakko Kogyo Co., Ltd. | Stabilizers for l-ascorbic acid-2-sodium phosphate |
DE10003786A1 (en) * | 2000-01-28 | 2001-08-02 | Merck Patent Gmbh | Galenic formulation |
GB0004686D0 (en) * | 2000-02-28 | 2000-04-19 | Aventis Pharma Ltd | Chemical compounds |
US20030203857A1 (en) * | 2000-04-11 | 2003-10-30 | Hiromu Ohnogi | Remedies |
BR0017224A (en) * | 2000-04-18 | 2003-01-07 | Ceteris Holding B V Amsterdam | Natural extract-based composition useful in preventing and treating skin wrinkles |
DE10025558A1 (en) * | 2000-05-24 | 2001-11-29 | Merck Patent Gmbh | Topical composition containing at least one aryloxime and process for its preparation |
DE10025553A1 (en) * | 2000-05-24 | 2001-11-29 | Merck Patent Gmbh | Composition containing at least one aryloxime and at least one active ingredient for the treatment of acne and their use |
ATE361083T1 (en) * | 2000-06-28 | 2007-05-15 | Kikkoman Corp | ANTIALLERGIC COMPOUNDS AND MEDICATIONS CONTAINING THEM, FOODS, BEVERAGES OR COSMETICS AND PROCESSES FOR THE PRODUCTION THEREOF |
DE10031457C2 (en) * | 2000-06-28 | 2002-12-12 | Jean Krutmann | Use of O-beta-hydroxyethylrutoside or its aglycon for the systemic treatment and prophylaxis of UV-induced dermatoses and undesirable long-term consequences of UV radiation |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10035071A1 (en) * | 2000-07-17 | 2002-01-31 | Cognis Deutschland Gmbh | Decorative cosmetic preparations |
FR2811892B1 (en) * | 2000-07-18 | 2003-04-18 | Oreal | COMPOSITION COMPRISING SOPHORA JAPONICA EXTRACT AND USE THEREOF |
JP3548102B2 (en) * | 2000-08-07 | 2004-07-28 | 花王株式会社 | Antihypertensive agent |
GB2368012A (en) * | 2000-10-19 | 2002-04-24 | Nicholas John Larkins | Preparation for the relief of inflammatory disease |
FR2815861B1 (en) * | 2000-10-26 | 2003-02-28 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND AT LEAST ONE ISOFLAVONOID FOR TREATING SKIN SIGNS OF AGING |
FR2815859B1 (en) * | 2000-10-26 | 2003-02-28 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID WITH PROVITAMIN ACTIVITY WITH AND AT LEAST ONE CAROTENOID WITHOUT PROVITAMIN ACTIVITY TO TREAT THE SIGNS OF AGING |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
US6630158B2 (en) | 2000-10-31 | 2003-10-07 | Stiefel Laboratories, Inc. | Dietary supplement composition and method for improving and maintaining healthy skin |
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
CN1262274C (en) * | 2000-11-14 | 2006-07-05 | 生命健康科学有限公司 | Complexes of phosphate derivatives |
DE10056400A1 (en) | 2000-11-14 | 2002-05-23 | Merck Patent Gmbh | Galenic formulation |
FR2816838B1 (en) * | 2000-11-17 | 2004-12-03 | Oreal | USE OF DERIVATIVES OF 2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID AS PRODESQUAMANTS |
DE10062401A1 (en) * | 2000-12-14 | 2002-06-20 | Beiersdorf Ag | Use of folic acid and / or derivatives thereof for the preparation of cosmetic or dermatological preparations for the prophylaxis of damage to the skin's own DNA and / or to repair damage already occurred to the skin's own DNA |
FR2818135B1 (en) * | 2000-12-15 | 2003-02-14 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE CAROTENOID |
FR2818148B1 (en) * | 2000-12-15 | 2005-06-24 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-KETO DHEA AND AT LEAST ONE ISOFLAVONOID |
US20040067245A1 (en) * | 2000-12-20 | 2004-04-08 | Harish Mahalingam | Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
JP4197091B2 (en) * | 2000-12-27 | 2008-12-17 | 花王株式会社 | Cosmetics |
WO2002062978A1 (en) * | 2001-02-05 | 2002-08-15 | David Holzer | Method and composition for in situ metabolizing of glutathione and nad |
FR2820974B1 (en) * | 2001-02-21 | 2004-02-13 | Pharmascience Lab | TOPICAL COMPOSITION COMPRISING A TRUE SOLUTION CONTAINING A CHROMANE OR CHROMENE DERIVATIVE, ITS PREPARATION METHOD AND ITS COSMETIC AND THERAPEUTIC USE |
WO2002067988A2 (en) | 2001-02-27 | 2002-09-06 | The Regents Of The University Of Michigan | Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
US6555143B2 (en) | 2001-02-28 | 2003-04-29 | Johnson & Johnson Consumer Products, Inc. | Legume products |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
JP4504619B2 (en) * | 2001-03-02 | 2010-07-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cosmetic preparation |
FR2822466B1 (en) * | 2001-03-23 | 2004-07-02 | Diana Ingredients | PHLORIDZINE-RICH PHENOLIC FRACTION AND ITS USE AS A COSMETIC, FOOD OR NUTRACEUTICAL AGENT |
WO2002078664A1 (en) * | 2001-03-30 | 2002-10-10 | Shiseido Co., Ltd. | Color-developing compositions and cosmetics, fregrance products and miscellaneous goods for display with the use of the same |
DK1249230T3 (en) * | 2001-04-12 | 2004-03-15 | Vesifact Ag | Microemulsion preconcentrates and microemulsions containing coenzyme Q10 |
EP1260212A1 (en) * | 2001-05-21 | 2002-11-27 | Cognis France S.A. | Cosmetic composition |
WO2002098376A1 (en) * | 2001-06-06 | 2002-12-12 | The Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes |
DE10133202A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
DE10133201A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing electrolytes in combination with polyols and/or urea to, e.g. improve skin condition or to treat or prevent skin disorders |
US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
MXPA04000654A (en) * | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents. |
CA2357053A1 (en) * | 2001-09-04 | 2003-03-04 | Unknown | Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease |
US20030118536A1 (en) * | 2001-11-06 | 2003-06-26 | Rosenbloom Richard A. | Topical compositions and methods for treatment of adverse effects of ionizing radiation |
US6696082B2 (en) * | 2002-01-08 | 2004-02-24 | Mccully Kilmer S. | Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier |
US20030224075A1 (en) * | 2002-02-21 | 2003-12-04 | Jue-Chen Liu | Soy composition for balancing combination skin |
FR2836336B1 (en) * | 2002-02-26 | 2004-08-27 | Diana Ingredients | USE IN A COSMETIC TREATMENT OF A PHENOLIC FRACTION RICH IN DIHYDROCHALCONES |
GB0209254D0 (en) * | 2002-04-23 | 2002-06-05 | Larkins Nicholas J | Preparation for the relief of disease |
US20030212127A1 (en) * | 2002-05-09 | 2003-11-13 | Bradley Pharmaceuticals, Inc. | Method of treating actinic keratosis |
DE10225772A1 (en) * | 2002-06-10 | 2003-12-24 | Beiersdorf Ag | Cosmetic or dermatological formulations for skin care after sunbathing or shaving |
KR20050059000A (en) * | 2002-06-25 | 2005-06-17 | 코즈메스틱 솔루션즈 프로퍼티 리미티드 | Topical cosmetic compositions |
AU2002950308A0 (en) * | 2002-07-23 | 2002-09-12 | Phoenix Eagle Company Pty Ltd | Topically applied composition |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US6793193B2 (en) * | 2002-08-20 | 2004-09-21 | Dart Industries Inc. | Adjustable mold for forming shaped food |
JP3926711B2 (en) * | 2002-08-30 | 2007-06-06 | 株式会社ファンケル | Composition for preventing skin aging to prevent, prevent and improve flattening of the epidermis |
DE10240923A1 (en) * | 2002-09-02 | 2004-03-04 | Merck Patent Gmbh | Flavonoid derivatives for eczema treatment |
US20040063593A1 (en) * | 2002-09-30 | 2004-04-01 | Wu Jeffrey M. | Compositions containing a cosmetically active organic acid and a legume product |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
ES2532906T5 (en) | 2002-10-25 | 2022-03-23 | Foamix Pharmaceuticals Ltd | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20160158261A1 (en) * | 2002-10-25 | 2016-06-09 | Foamix Pharmaceuticals Ltd. | Antibiotic Kit and Composition and Uses Thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
DE20217814U1 (en) * | 2002-11-18 | 2004-04-08 | Asat Ag Applied Science & Technology | Melatonin daily dosage units |
DE10250646A1 (en) * | 2002-10-30 | 2004-05-13 | Asat Ag Applied Science & Technology | Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents |
MXPA05004535A (en) * | 2002-10-30 | 2005-11-23 | Asat Ag Applied Science & Tech | Daily melatonin dosing units. |
US7083813B2 (en) * | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
US20040205904A1 (en) * | 2002-12-13 | 2004-10-21 | L'oreal | Dye composition comprising a cationic tertiary para-phenylenediamine and a vitamin derivative, processes therefor and uses thereof |
DE10308162A1 (en) * | 2003-02-26 | 2004-09-09 | Universitätsklinikum Freiburg | Process for the preparation of flavonoid-containing compositions and their use |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US20050036972A1 (en) * | 2003-03-10 | 2005-02-17 | Hy-Gene Biomedical Corporation | System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations |
WO2004080208A1 (en) * | 2003-03-11 | 2004-09-23 | Kaneka Corporation | Oil-in-water type emulsion containing coenzyme q10 and process for producing the same |
ITFI20030070A1 (en) * | 2003-03-18 | 2004-09-19 | Berlin Chemie Ag | STABILIZED TOPICAL FORMULATIONS CONTAINING KETOPROFENE |
DE20305898U1 (en) | 2003-04-03 | 2003-07-31 | Orantek, Katharina, 60488 Frankfurt | Pharmaceutical compositions include vitamins and optionally trace elements to enhance the therapeutic effect and/or reduce the side effects of drugs |
ITMI20030661A1 (en) * | 2003-04-04 | 2004-10-05 | Indena Spa | PROCESS FOR THE PREPARATION OF FERUTININ FROM PLANTS OF THE GENE FERULA |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20050008588A1 (en) * | 2003-06-05 | 2005-01-13 | L'oreal | Aminoarylvinyl-s-triazine compounds and uses thereof |
US20040258765A1 (en) * | 2003-06-23 | 2004-12-23 | Gee Gilbert C. | Method for treatment of sores and lesions of the skin |
US7001622B1 (en) | 2003-06-30 | 2006-02-21 | Robert Berndt | Composition and method for treatment and prevention of pruritis |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
US20050004561A1 (en) * | 2003-07-01 | 2005-01-06 | Lynn Halas | Method for removing hair |
AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
WO2005007676A2 (en) * | 2003-07-10 | 2005-01-27 | Rajadhyaksha V J | Glycopeptides for the treatment of als and other metabolic and autoimmune disorders |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US7546987B2 (en) * | 2003-08-20 | 2009-06-16 | Howard Sinkoff | Cable tray assemblies |
US7999003B2 (en) * | 2003-08-26 | 2011-08-16 | Mannatech, Incorporated | Antioxidant compositions and methods thereto |
US20050214413A1 (en) * | 2003-08-26 | 2005-09-29 | Mannatech, Inc. | Methods and compositions for modified release of nutritional supplements |
US20050048012A1 (en) * | 2003-08-26 | 2005-03-03 | Roland Jermann | Use of biotin or a biotin derivative for skin lightening purposes and for the treatment of senile lentigines |
US8211873B2 (en) * | 2003-08-29 | 2012-07-03 | Island Kinetics, Inc. | Antiaging chirally-correct mitoprotectant amino acid and peptide complexes |
US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
EP1677748A1 (en) * | 2003-10-29 | 2006-07-12 | Johnson & Johnson Consumer France SAS | Compositions comprising soy products and dioic acids |
KR100449887B1 (en) * | 2003-10-31 | 2004-09-22 | 주식회사 렉스진바이오텍 | Preparation method of extract of Sophorae Fructus containing isoflavone |
NZ547628A (en) * | 2003-11-06 | 2010-07-30 | Univ New York State Res Found | Methods of treating eczema |
ES2232302B1 (en) * | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | MYO-INOSITOL HEXAFOSFATO FOR TOPICAL USE. |
JP4256389B2 (en) * | 2003-11-17 | 2009-04-22 | セダーマ | Composition comprising a mixture of tetrapeptide and tripeptide |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
US20050152996A1 (en) * | 2003-12-01 | 2005-07-14 | BUTLER Donald | Extracts of Mimulus aurantiacus for treating psoriasis and repelling insects |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
AU2004312072B2 (en) | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
EP1703795A4 (en) * | 2003-12-31 | 2011-01-19 | Yosi Shevach | Beta vulgaris-based products |
DE602005025979D1 (en) * | 2004-03-03 | 2011-03-03 | Vital Health Sciences Pty Ltd | ALKALOID FORMULATIONS |
FR2869229B1 (en) * | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | USE OF A INDUCER OF UGT BY TOPIC |
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
US7399493B2 (en) * | 2004-07-16 | 2008-07-15 | Wille John J | Anti-irritant botanicals |
EP1771149A1 (en) * | 2004-07-23 | 2007-04-11 | The Procter and Gamble Company | Skin care composition containing a flavonoid and vitamin b3 |
CN1988879A (en) * | 2004-07-23 | 2007-06-27 | 宝洁公司 | Skin care composition containing a flavonoid and vitamin b3 |
WO2006020165A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Skin care composition containing a flavonoid and vitamin b3 |
US20060018861A1 (en) * | 2004-07-23 | 2006-01-26 | Minghua Chen | Skin care composition |
JP2008507525A (en) * | 2004-07-23 | 2008-03-13 | ザ プロクター アンド ギャンブル カンパニー | Substrate-based skin care device |
JP4672303B2 (en) * | 2004-08-02 | 2011-04-20 | 丸善製薬株式会社 | Fibroblast growth promoter, skin cosmetics and cosmetics |
BRPI0513673B8 (en) * | 2004-08-03 | 2021-07-27 | Vital Health Sciences Pty Ltd | method for producing a drug to increase the efficacy and transport of enterally administered biologically active compounds, and pharmaceutical composition |
US7368133B2 (en) * | 2004-08-23 | 2008-05-06 | Yu Ching Wu | Medicinal drug and methods of manufacturing the same |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US9089494B2 (en) * | 2004-09-14 | 2015-07-28 | Coty S.A. | Ultra-violet inhibition system |
EP1799228B1 (en) | 2004-09-14 | 2010-04-14 | Ajinomoto Omnichem S.A. | Topical compositions containing phosphorylated polyphenols |
US20080262080A1 (en) * | 2004-10-05 | 2008-10-23 | Kyushu University, National University Corporation | Allergy Suppressive Agent |
WO2006060548A2 (en) * | 2004-12-02 | 2006-06-08 | Ebersytes, Llc | Novel dermatological composition using bio-activating organocatalysts |
JP2008523074A (en) * | 2004-12-07 | 2008-07-03 | アクセス ビジネス グループ インターナショナル エルエルシー | Method for removing nitric oxide and oxygen species with antioxidant fragrances |
CA2593537A1 (en) * | 2005-01-12 | 2006-07-20 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
MX2007008573A (en) * | 2005-01-14 | 2008-01-14 | Lipo Chemicals Inc | Composition and method for treating hyperpigmented skin. |
US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
KR20070108382A (en) * | 2005-03-03 | 2007-11-09 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Compounds having anti-cancer properties |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
US8372040B2 (en) | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
DE102005026002A1 (en) * | 2005-06-03 | 2006-12-14 | Beiersdorf Ag | Cosmetic preparations containing an aqueous aniseed extract and one or more polymeric thickening agents selected from the group of cellulose derivatives |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
EP1893159B1 (en) | 2005-06-17 | 2015-09-30 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents |
US7700083B2 (en) * | 2005-10-24 | 2010-04-20 | Kevin Meehan | Skin care composition for accelerated production of collagen proteins and method of fabricating same |
US7767238B2 (en) | 2005-11-04 | 2010-08-03 | Pepsico, Inc. | Beverage composition and method of preventing degradation of vitamins in beverages |
EP1797861A1 (en) * | 2005-12-16 | 2007-06-20 | KPSS-Kao Professional Salon Services GmbH | Composition for the permanent shaping of human hair |
DE102006010870A1 (en) * | 2006-03-07 | 2007-09-13 | Henkel Kgaa | Cosmetic agents with purine and / or purine derivatives I |
DE102006010869A1 (en) * | 2006-03-07 | 2007-09-20 | Henkel Kgaa | Cosmetic agents with purine and / or purine derivatives II |
US20070225360A1 (en) * | 2006-03-22 | 2007-09-27 | L'oreal | Anti-aging composition containing phloretin |
US20080008818A1 (en) * | 2006-06-23 | 2008-01-10 | Miri Seiberg | Partially denatured whole soybean extracts and methods of use thereof |
KR100772494B1 (en) * | 2006-08-09 | 2007-11-01 | 한국원자력연구원 | Therapeutic hydrogels for atopic dermatitis using irradiation |
KR100808552B1 (en) * | 2007-02-01 | 2008-02-29 | 한국원자력연구원 | Therapeutic hydrogels for atopic dermatitis containing covering layer to prevent water loss |
WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
FR2906716B1 (en) * | 2006-10-06 | 2013-05-17 | Clarins Lab | USE OF A COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN. |
US20080089960A1 (en) * | 2006-10-16 | 2008-04-17 | Miri Seiberg | Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage |
JP2007056035A (en) * | 2006-10-19 | 2007-03-08 | Fancl Corp | Differentiation inhibiting agent for normal keratinized human epithelium cell |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080135643A1 (en) * | 2006-12-08 | 2008-06-12 | Kimberly-Clark Worldwide, Inc. | Pulsating spray dispensers |
US20080147734A1 (en) * | 2006-12-18 | 2008-06-19 | Cuticeuticals, Inc | Method of topical steroidal organization |
DE102006061828A1 (en) * | 2006-12-21 | 2008-06-26 | Henkel Kgaa | Oxidative Hair Treatment with Litchi Extract |
US20080167277A1 (en) * | 2006-12-29 | 2008-07-10 | Charles Conrad | Methods of treating skin disorders with caffeic acid analogs |
EP2011479A1 (en) * | 2007-06-26 | 2009-01-07 | KPSS-Kao Professional Salon Services GmbH | Composition for the permanent shaping of human hair |
EP2011543A1 (en) * | 2007-06-26 | 2009-01-07 | KPSS-Kao Professional Salon Services GmbH | Composition for the permanent shaping of human hair |
EP2011478A1 (en) * | 2007-06-26 | 2009-01-07 | KPSS-Kao Professional Salon Services GmbH | Composition for the permanent shaping of human hair |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US20090149530A1 (en) * | 2007-08-17 | 2009-06-11 | Alberte Randall S | Antiinfective Flavonol Compounds and Methods of Use Thereof |
US7802314B2 (en) * | 2007-10-31 | 2010-09-28 | Kimberly-Clark Worldwide, Inc. | Hand-wear article with cutaneous sensory elements |
US8221370B2 (en) * | 2007-10-31 | 2012-07-17 | Kimberly-Clark Worldwide, Inc. | Personal care article with substrate surface topography for evoking a neurosensory skin response |
WO2009060017A1 (en) * | 2007-11-09 | 2009-05-14 | Henkel Ag & Co. Kgaa | Hair treatment agent comprising tiliroside and vitamin b |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
JP5227016B2 (en) * | 2007-12-28 | 2013-07-03 | ライオン株式会社 | Itching inhibitor and itch inhibiting composition |
EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20090324705A1 (en) * | 2008-02-13 | 2009-12-31 | Nina Vikhrieva | Phytonutrient compositions for topical use |
US20090215924A1 (en) * | 2008-02-26 | 2009-08-27 | Momentive Performance Materials Inc. | Silicone rubber exhibiting effective antimicrobial activity |
MX2010011997A (en) * | 2008-04-30 | 2011-02-25 | Procter & Gamble | Hair care compositions for preventing oxidative damage to hair, methods of use, and methods of marketing such compositions. |
US8450337B2 (en) * | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
CA2723787A1 (en) * | 2009-01-30 | 2010-08-05 | Vitrogen, S.A. | Agent for cutaneous photoprotection against uva/uvb rays |
FR2942961B1 (en) * | 2009-03-11 | 2011-04-22 | Oreal | COSMETIC COMPOSITION CONTAINING A DIBENZOYLMETHANE DERIVATIVE AND DIHYDROCHALCONE; METHOD FOR PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE DERIVATIVE |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
GB2471135A (en) * | 2009-06-19 | 2010-12-22 | H D S Ltd | Hair dye composition and use in reducing contact allergy |
CN102803682B (en) * | 2009-06-22 | 2016-05-04 | 唐纳森公司 | Filter element supporting component, quick-mount system and method |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
KR20110012148A (en) * | 2009-07-30 | 2011-02-09 | 서울대학교산학협력단 | Hydroxycinnamoyl-peptide derivatives, process for producing the same and cosmetic composition comprising the same |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
JP2011148708A (en) * | 2010-01-19 | 2011-08-04 | Noevir Co Ltd | Moisturizing agent, anti-ageing agent, antioxidative agent, slimming agent, beautifying and whitening agent, anti-inflammatory agent, immunoactivating agent, skin care preparation for external use and functional oral administration composition |
US20140135372A1 (en) | 2010-02-02 | 2014-05-15 | Elliott Farber | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
WO2011094814A1 (en) | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
JP2011168559A (en) * | 2010-02-22 | 2011-09-01 | Noevir Co Ltd | Antioxidant, anti-inflammatory agent, anti-aging agent, skin care preparation for external use and functional oral composition |
MX2012011355A (en) | 2010-03-30 | 2012-11-30 | Phosphagenics Ltd | Transdermal delivery patch. |
EP2575456B1 (en) | 2010-05-28 | 2016-05-04 | Galderma S.A. | Compositions and methods for treating bruises |
JP2012082183A (en) * | 2010-10-06 | 2012-04-26 | Masaaki Ishiwatari | Surfactant free oil-in-water type emulsified composition, and surfactant free cosmetic |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
ITCN20110006A1 (en) * | 2011-06-16 | 2012-12-17 | Alpiflor S R L | NUTRITIONAL COMPOSITION IN WHICH THEY ARE ASSOCIATED IN A TWO PREPARED KIT, ONE WITH A PREBIOTIC, D-MANNOSE AND CITRATES AND THE OTHER WITH D-MANNOSE AND BIOFLAVONOIDS. |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
JP2013018720A (en) * | 2011-07-08 | 2013-01-31 | Kao Corp | Hair treatment composition |
US10111821B2 (en) | 2011-11-03 | 2018-10-30 | Applied Biology, Inc. | Methods and compositions for administering a specific wavelength phototherapy |
US20130115180A1 (en) * | 2011-11-03 | 2013-05-09 | Andy Ofer GOREN | Methods And Compositions For Administering A Specific Wavelength Phototherapy |
EA031552B1 (en) * | 2011-12-20 | 2019-01-31 | Орифлейм Ресёрч Энд Девелопмент Лтд. | Non-therapeutic cosmetic topical application of n-acetyl-l-aspartic acid |
JP2012092138A (en) * | 2011-12-27 | 2012-05-17 | Maruzen Pharmaceut Co Ltd | Skin cosmetic and hair cosmetic |
WO2013132668A1 (en) * | 2012-03-08 | 2013-09-12 | サントリーホールディングス株式会社 | Composition comprising imidazole peptide and quercetin glycoside |
CN102659876B (en) * | 2012-05-14 | 2014-06-11 | 河南中医学院 | Flavonoid glycoside extracted from cardamine tangutorum and preparation method thereof |
US9072919B2 (en) * | 2012-10-12 | 2015-07-07 | L'oreal S.A. | Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
EP2769708A1 (en) * | 2013-02-21 | 2014-08-27 | Symrise AG | Inhibition of skin ageing induced by IR radiation |
CA2907703A1 (en) * | 2013-03-20 | 2014-09-25 | The Procter & Gamble Company | Articles of manufacture comprising water-soluble polymer particles and processes for making same |
JP6343126B2 (en) * | 2013-05-14 | 2018-06-13 | 森永製菓株式会社 | Method for stabilizing stilbenes contained in plant extract or solution thereof, and plant extract containing stilbenes or solution thereof |
JP6209360B2 (en) * | 2013-05-14 | 2017-10-04 | 森永製菓株式会社 | Piceatannol solution and method for stabilizing piceatannol solution |
US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
WO2015083554A1 (en) * | 2013-12-02 | 2015-06-11 | 株式会社林原 | 4G-O-α-D-GLUCOPYRANOSYLRUTIN CRYSTAL AND APPLICATION THEREOF |
AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
DE102014104254A1 (en) * | 2014-03-26 | 2015-10-01 | Beiersdorf Ag | Active ingredient combinations of 4-hydroxyacetophenone and one or more cinnamic acid derivatives, as well as cosmetic or dermatological preparations containing these active ingredient combinations |
EP3131546B1 (en) * | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs) |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
ES2882588T3 (en) * | 2015-03-31 | 2021-12-02 | Turtle Bear Holdings Llc | Antiviral activity of medicinal mushrooms and their active constituents |
AU2016367708B2 (en) | 2015-12-09 | 2022-07-14 | Phosphagenics Limited | Pharmaceutical formulation |
WO2017117099A1 (en) | 2015-12-29 | 2017-07-06 | L'oreal | Stable antioxidant compositions |
CA3056759C (en) | 2016-03-22 | 2024-01-23 | Avicenna Nutraceutical, Llc | Hydrolyzed collagen compositions and methods of making thereof |
US10695278B2 (en) | 2016-03-31 | 2020-06-30 | L'oreal | Photo-stabilized compositions and methods of use |
US20170326062A1 (en) | 2016-05-13 | 2017-11-16 | Yi-Chun Lin | Compositions for skin application |
CN109640939A (en) * | 2016-06-29 | 2019-04-16 | 日光化学株式会社 | Damage hair improver and the damage hair improvement cosmetics containing it |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
CA3038697A1 (en) * | 2016-10-13 | 2018-04-19 | Unilever Plc | Anti-dandruff composition |
KR102647670B1 (en) | 2016-12-21 | 2024-03-15 | 아베초 바이오테크놀로지 리미티드 | method |
JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Device and method for transdermal drug delivery |
DE102017201306A1 (en) | 2017-01-27 | 2018-08-02 | Beiersdorf Ag | Stabilization of preparations containing alpha-glucosylrutin |
EP3158989A3 (en) * | 2017-02-01 | 2017-10-11 | SanderStrothmann GmbH | Cosmetic skin treatment composition |
KR101782966B1 (en) * | 2017-03-14 | 2017-09-28 | 전북대학교산학협력단 | A Composition for Preventing or Treating Pruritus |
JP6482604B2 (en) * | 2017-06-22 | 2019-03-13 | 教裕 南郷 | Inner skin dissolution type needle and needle device |
US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
WO2019148116A1 (en) | 2018-01-29 | 2019-08-01 | Atolla Skin Health, Inc. | Systems and methods for formulating personalized skincare products |
US10729633B2 (en) * | 2018-03-29 | 2020-08-04 | L'oreal | Methods for boosting UVA photo-protection using antioxidants |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
JP7292866B2 (en) * | 2018-12-11 | 2023-06-19 | ロレアル | Less Odorless Composition |
KR20200091271A (en) * | 2019-01-22 | 2020-07-30 | 조선대학교산학협력단 | Composition for regulating skin hypersensitivity comprising hesperetin |
US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
JP2021161064A (en) * | 2020-03-31 | 2021-10-11 | 築野ライスファインケミカルズ株式会社 | Discoloration-suppressing composition of ferulic acid |
CN116437894A (en) * | 2020-08-31 | 2023-07-14 | 莱雅公司 | Composition for caring keratin materials |
WO2023018959A1 (en) * | 2021-08-12 | 2023-02-16 | Roc Opco Llc | Composition of hyaluronic acid and use alone and in combination with retinoids to improve skin |
US20230364133A1 (en) * | 2022-05-10 | 2023-11-16 | Melaleuca, Inc. | Dietary supplement compositions |
WO2023229987A1 (en) * | 2022-05-25 | 2023-11-30 | Neuvian LLC | Vaginal care compositions comprising exosomes and its uses for improving vaginal health |
WO2024135577A1 (en) | 2022-12-23 | 2024-06-27 | L'oreal | Stable dispersion composition comprising retinoid |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US504323A (en) * | 1893-09-05 | btje kle | ||
DE2529511A1 (en) * | 1975-07-02 | 1977-01-20 | Henkel & Cie Gmbh | SUN PROTECTION FOR HUMAN SKIN |
US4297348A (en) * | 1980-04-11 | 1981-10-27 | Rush-Hampton Industries, Inc. | Composition and method for the treatment of acne |
US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
DE3314895A1 (en) * | 1983-04-25 | 1984-10-25 | Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz | DENTAL AND ORAL CARE PRODUCTS |
FR2556969B1 (en) * | 1983-12-27 | 1986-04-25 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION BASED ON PLANT EXTRACTS HAVING ACTION ON HAIR FRAGILITY |
JPH0623089B2 (en) * | 1986-05-15 | 1994-03-30 | 株式会社資生堂 | External skin preparation |
LU86601A1 (en) * | 1986-09-22 | 1988-04-05 | Oreal | PHOTOSTABLE COSMETIC COMPOSITION CONTAINING AN ETHYLRUTINE DERIVATIVE AS A PROTECTIVE AGENT AGAINST SALARY LIGHT AND ITS USE FOR PROTECTING THE SKIN AND HAIR |
IT1201149B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | BIOFLAVONOID COMPLEXES WITH PHOSPHOLIPIDS, THEIR PREPARATION, USE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS |
FR2610626B1 (en) * | 1987-02-09 | 1989-05-19 | Oreal | NOVEL ANTI-OXIDIZER SYSTEM BASED ON A STABILIZED ASCORBYL ESTER, COMPRISING AT LEAST ONE COMPLEXING AGENT AND AT LEAST ONE THIOL, AND COMPOSITIONS CONTAINING SUCH ANTI-OXIDIZING SYSTEM |
JPS63208506A (en) * | 1987-02-24 | 1988-08-30 | Nonogawa Shoji:Kk | Cosmetic |
US5008441A (en) * | 1987-08-04 | 1991-04-16 | The Trustees Of Columbia University In The City Of New York | Caffeic acid esters and methods of producing and using same |
JPH0196106A (en) * | 1987-10-09 | 1989-04-14 | Shiseido Co Ltd | External drug for skin |
FR2634779B1 (en) * | 1988-07-29 | 1994-05-27 | Oreal | NOVEL ANTI-OXIDIZING SYSTEM BASED ON A STABILIZED ASCORBYL ESTER, CONTAINING, AT LEAST ONE TOCOPHEROL OR A MIXTURE OF TOCOPHEROLS OR CAFEIC ACID OR A DERIVATIVE THEREOF, AT LEAST ONE COMPLEX AGENT AND AT LEAST ONE NON-THIOLE POLYPEPTIDE, AND COMPOSITIONS CONTAINING SUCH ANTI-OXIDIZING SYSTEM |
US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
ES2071010T3 (en) * | 1989-03-08 | 1995-06-16 | Hayashibara Biochem Lab | PREPARATION AND USES OF THE ALPHA-GLYCOSYL ROUTINE. |
JP3060227B2 (en) * | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α-Glycosyl hesperidin, its production method and use |
JPH03255013A (en) * | 1990-03-01 | 1991-11-13 | San Ei Chem Ind Ltd | Cosmetic |
FR2671724A1 (en) * | 1991-01-22 | 1992-07-24 | Synthelabo | EXTRACTS OF HAMAMELIS LEAVES, THEIR PREPARATION AND THEIR APPLICATIONS. |
CA2102689A1 (en) * | 1991-03-21 | 1992-09-22 | Claude Andary | Novel caffeic acid derivative, oraposide, and cosmetic or pharmaceutic, especially dermatological, composition containing it |
US5561116A (en) * | 1991-04-11 | 1996-10-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Solid product containing propolis components, and preparation and uses thereof |
JP3134233B2 (en) * | 1991-07-26 | 2001-02-13 | 株式会社林原生物化学研究所 | α-Glycosyl quercetin, its production method and use |
IL99291A (en) * | 1991-08-23 | 1997-04-15 | Fischer Pharma Ltd | Cosmetic preparations |
US5494667A (en) * | 1992-06-04 | 1996-02-27 | Kabushiki Kaisha Hayahibara | Topically applied hair restorer containing pine extract |
US5340568A (en) * | 1992-07-01 | 1994-08-23 | The Procter & Gamble Company | Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles |
JP3241440B2 (en) * | 1992-07-02 | 2001-12-25 | 有限会社野々川商事 | Cosmetics |
EP0577143B1 (en) * | 1992-07-03 | 1999-01-27 | ALFATEC-PHARMA GmbH | Solid and liquid solutions of flavonoids |
FR2697159B1 (en) * | 1992-10-22 | 1995-01-13 | Oreal | Cosmetic or dermo-pharmaceutical composition containing in combination a lauroylmethionate of a basic amino acid and at least one polyphenol. |
FR2699818B1 (en) * | 1992-12-24 | 1995-02-03 | Oreal | Cosmetic or pharmaceutical composition containing in combination a polyphenol and an extract of gingko. |
US5446452A (en) * | 1993-02-05 | 1995-08-29 | Litton; Charles J. | Temperature monitoring system |
US5358752A (en) * | 1993-02-23 | 1994-10-25 | Norac Technologies Inc. | Skin care composition |
DE4307983A1 (en) * | 1993-03-13 | 1994-09-15 | Beiersdorf Ag | Active ingredients and cosmetic and dermatological preparations |
CN1123523A (en) * | 1993-04-20 | 1996-05-29 | 普罗克特和甘保尔公司 | Methods of using hesperetin for sebum control and treatment of ACNE |
FR2707491B1 (en) * | 1993-07-02 | 1995-12-01 | Oreal | Cosmetic composition containing in combination a superoxide dismutase and a melanin pigment. |
FR2718022B1 (en) * | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Cosmetic or dermatological compositions and their preparation. |
DE4444238A1 (en) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
FR2736829B1 (en) * | 1995-07-20 | 1997-09-12 | Oreal | COMPOSITION FOR FIGHTING AGAINST SPOTS AND / OR AGING OF THE SKIN, USES THEREOF |
-
1994
- 1994-12-13 DE DE4444238A patent/DE4444238A1/en not_active Withdrawn
-
1995
- 1995-11-23 EP EP95118438A patent/EP0716847A1/en not_active Withdrawn
- 1995-12-08 JP JP7345018A patent/JPH08259421A/en active Pending
- 1995-12-12 DE DE59510219T patent/DE59510219D1/en not_active Revoked
- 1995-12-12 DE DE29522371U patent/DE29522371U1/en not_active Expired - Lifetime
- 1995-12-12 WO PCT/EP1995/004908 patent/WO1996018382A1/en not_active Application Discontinuation
- 1995-12-12 EP EP95942128A patent/EP0799022A1/en not_active Withdrawn
- 1995-12-12 AT AT95942129T patent/ATE240092T1/en not_active IP Right Cessation
- 1995-12-12 US US08/849,523 patent/US5952373A/en not_active Expired - Fee Related
- 1995-12-12 EP EP01123102A patent/EP1201227A3/en not_active Withdrawn
- 1995-12-12 WO PCT/EP1995/004907 patent/WO1996018381A1/en not_active Application Discontinuation
- 1995-12-12 EP EP95942130A patent/EP0799023B1/en not_active Revoked
- 1995-12-12 US US08/849,524 patent/US6121243A/en not_active Expired - Fee Related
- 1995-12-12 ES ES95942130T patent/ES2177673T3/en not_active Expired - Lifetime
- 1995-12-12 AT AT95942130T patent/ATE218059T1/en not_active IP Right Cessation
- 1995-12-12 DE DE59510687T patent/DE59510687D1/en not_active Revoked
- 1995-12-12 JP JP8518256A patent/JPH10510522A/en not_active Ceased
- 1995-12-12 JP JP8518259A patent/JPH10510803A/en active Pending
- 1995-12-12 WO PCT/EP1995/004905 patent/WO1996018379A1/en not_active Application Discontinuation
- 1995-12-12 JP JP8518258A patent/JPH10510802A/en not_active Ceased
- 1995-12-12 US US08/849,525 patent/US20020142012A1/en not_active Abandoned
- 1995-12-12 EP EP02025465A patent/EP1300138A3/en not_active Withdrawn
- 1995-12-12 EP EP95942129A patent/EP0797427B1/en not_active Revoked
- 1995-12-12 JP JP8518257A patent/JPH10510523A/en active Pending
- 1995-12-12 ES ES95942129T patent/ES2199260T3/en not_active Expired - Lifetime
- 1995-12-12 DE DE29522375U patent/DE29522375U1/en not_active Expired - Lifetime
- 1995-12-12 EP EP95941094A patent/EP0799020A1/en not_active Ceased
- 1995-12-12 WO PCT/EP1995/004906 patent/WO1996018380A1/en not_active Application Discontinuation
-
1999
- 1999-05-06 US US09/306,067 patent/US6180662B1/en not_active Expired - Fee Related
- 1999-11-30 US US09/451,262 patent/US6423747B1/en not_active Expired - Fee Related
-
2000
- 2000-03-30 US US09/540,007 patent/US6562794B1/en not_active Expired - Fee Related
-
2002
- 2002-04-23 US US10/128,766 patent/US6596761B2/en not_active Expired - Fee Related
-
2009
- 2009-01-16 US US12/355,367 patent/US20090131340A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9618379A1 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0799020A1 (en) | Cosmetic and dermatological preparations with flavonoids | |
EP1296642B1 (en) | Use of creatine and/or creatine derivatives in dermatological preparations | |
EP0945126B1 (en) | Cosmetic or dermatologic composition containing carnitine and/or an acylcarnitine and at least an antioxidant | |
EP1594455B1 (en) | Cosmetic or dermatological preparations containing creatine, creatinine and/or the derivatives thereof combined with soya bean extracts | |
EP1194115A1 (en) | Topically applied idebenone-containing agent with protective and regenerative effect | |
WO2002009652A2 (en) | Cosmetic or dermatological active ingredient combinations containing carnitine and the use thereof | |
DE102004032837A1 (en) | Use of active compound combinations of one or more biochinones and one or more isoflavones for improving the skin contours | |
DE10136076A1 (en) | Cosmetic or dermatological preparations containing creatinine or its derivative, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis | |
EP1000603B1 (en) | Use of surface-active citric acid esters for stabilizing flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
DE19806946A1 (en) | Combination of (acyl) carnitine and retinoid for use in skin care, effective e.g. against light-induced damage and inflammation | |
EP0998898B1 (en) | Use of alkylglycosides for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
EP0995422A1 (en) | Use of nitrilotriacetic acid for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
DE10316666B4 (en) | Cosmetic or dermatological preparations with a combination of creatinine with creatine and coenzyme Q10 | |
DE29522372U1 (en) | Cosmetic and dermatological preparations with flavonoids | |
EP0995432A1 (en) | Use of surfactants for stabilizing flavones, flavanones, flavanoids, synergistic compositions of flavones, flavanones, flavanoides and surfactants, use of said compositions in cosmetic or dermatological formulations | |
DE19845266A1 (en) | Use of butylhydroxytoluene for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations | |
DE19739044A1 (en) | Use of di:hydro-robinetin as antioxidant and/or radical scavenger | |
EP0997133A1 (en) | Use of 2-tert-butylhydroquinone for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them | |
DE10127432A1 (en) | Cosmetic or dermatological preparations for combating undesirable skin pigmentation, containing synergistic combination of tyrosine-O-sulfate ester (or analog) and alpha-lipoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20000203 |
|
APAB | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPE |
|
APAB | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPE |
|
APAD | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOS REFNE |
|
APAB | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPE |
|
APAD | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOS REFNE |
|
APBX | Invitation to file observations in appeal sent |
Free format text: ORIGINAL CODE: EPIDOSNOBA2E |
|
APBX | Invitation to file observations in appeal sent |
Free format text: ORIGINAL CODE: EPIDOSNOBA2E |
|
APBZ | Receipt of observations in appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNOBA4E |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20040514 |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |